Latest News from: American Association for the Study of Liver Diseases (AASLD)

Filters close
Released: 30-Jan-2023 2:00 PM EST
AASLD Announces Dr. Joseph K. Lim as New Editor-in-Chief of Clinical Liver Disease
American Association for the Study of Liver Diseases (AASLD)

The American Association for the Study of Liver Diseases (AASLD) is pleased to announce that Dr. Joseph K. Lim, MD, FAASLD of Yale University will serve as the next Editor-in-Chief of Clinical Liver Disease (CLD), a free multimedia review journal that aims to provide education for clinicians diagnosing and managing patients with liver disease.

Released: 27-Jan-2023 11:30 AM EST
AASLD Hepatology Award with Harold Amos Medical Faculty Development Program
American Association for the Study of Liver Diseases (AASLD)

In support of our unwavering commitment to champion diversity, equity and inclusion in the field of hepatology, AASLD is pleased to announce the development of our own hepatology award.

Released: 18-Jan-2023 9:35 AM EST
Liver Associations Join Forces for Groundbreaking Viral Hepatitis Summit
American Association for the Study of Liver Diseases (AASLD)

Join the greatest minds in hepatology across the continent for a game-changing two-day event, the 2023 North American Viral Hepatitis Elimination Summit, on March 24-25 in Los Angeles.

Released: 23-Sep-2022 10:05 AM EDT
Industry Colloquium: The Future of Liver Preservation: Perspectives, Advances and Perfusion Device Workshop
American Association for the Study of Liver Diseases (AASLD)

New advances around perfusion devices are changing the game by keeping transplant livers alive longer, allowing for transportation of longer distances. New technology also enhances marginal donor livers, keeping them stimulated and alive longer, and therefore making many more livers available for transplantation. This in-person conference will provide groundbreaking insights on the technology and techniques around the use of preservation devices and examine the different strategies for successful perfusion/preservation of donor livers.

Released: 15-Aug-2022 3:25 PM EDT
AASLD Foundation Funds Over $1.5 Million in Hepatology Research and Career Development in 2022
American Association for the Study of Liver Diseases (AASLD)

The American Association for the Study of Liver Diseases (AASLD) Foundation, the largest medical society supporter of liver disease research and training in the United States, today announced its combined investment of over $1.5 million in Research and Career Development Awards, Abstract Awards, Emerging Liver Scholars (ELS) Program for medical residents and its new Emerging Liver Advanced Practice Provider (APP) Program. The 2022 award recipients — selected from a highly competitive applicant pool — demonstrate both exceptional aptitude and deep interest in liver disease research and treatment. Their work will further advance the mission of the AASLD Foundation and hepatology as a medical specialty.

8-Nov-2021 4:05 PM EST
Non-Overweight Patients with Nonalcoholic Fatty Liver Disease, Diabetes Fare Worse Than Overweight Patients Before and After Liver Transplant
American Association for the Study of Liver Diseases (AASLD)

ALEXANDRIA, Va. – A new study has found that people with nonalcoholic fatty liver disease (NAFLD) cirrhosis who are not overweight and are on a waiting list for a liver transplant fare worse than overweight patients before and after transplant surgery. The study concludes that these at-risk patients need better nutritional counseling and other interventions to help prevent serious health problems while they are waiting for liver transplant.

8-Nov-2021 4:05 PM EST
New Study Reveals Women, Minority Hepatologists Face Workplace Discrimination, Unequal Pay and Lack of Promotion Opportunities
American Association for the Study of Liver Diseases (AASLD)

ALEXANDRIA, Va. – A new study has found that hepatologists in the U.S., particularly women and racial and ethnic minorities, commonly experience workplace discrimination, such as exclusion from decision-making, disrespectful treatment by other staff members and unequal pay, benefits and promotion opportunities. The study will be presented this week at The Liver Meeting Digital Experience® held by the American Association for the Study of Liver Diseases (AASLD).

   
8-Nov-2021 4:05 PM EST
The Need for Liver Transplants Is Skyrocketing Among Older Americans
American Association for the Study of Liver Diseases (AASLD)

ALEXANDRIA, Va. – A new study has found that the proportion of older Americans who need a liver transplant (LT) has sharply increased in recent years, often due to the rising number of cases of nonalcoholic steatohepatitis (NASH). As the U.S. population ages, researchers estimate that more patients aged 65 or older will need an LT than ever before.

8-Nov-2021 4:05 PM EST
Nearly One-Fifth of Cirrhosis Patients Prescribed Opioids During Clinic Visits
American Association for the Study of Liver Diseases (AASLD)

ALEXANDRIA, Va. – A new study has found that among patients with cirrhosis, a late-stage liver disease, almost one in five outpatient clinic visits involve an opioid prescription. The study, presented this week at The Liver Meeting Digital Experience™ held by the American Association for the Study of Liver Diseases, also suggests that most of the physicians who prescribe opioids for patients with cirrhosis are not gastroenterologists or hepatologists, raising concerns those physicians may be less familiar with the potentially harmful effects of opioid drugs in patients with liver disease.

8-Nov-2021 4:05 PM EST
Higher Risk of Liver Cancer in People with Nonalcoholic Fatty Liver Disease Linked to High Blood Iron Levels
American Association for the Study of Liver Diseases (AASLD)

ALEXANDRIA, Va. – New research has found that patients with nonalcoholic fatty liver disease (NAFLD) who have high blood iron levels are at an elevated risk to develop the most common type of liver cancer, hepatocellular carcinoma (HCC). Researchers at the University of Pittsburgh will present their findings this week at The Liver Meeting Digital Experience™ held by the American Association for the Study of Liver Diseases.

Released: 19-Aug-2021 9:00 AM EDT
American Association for the Study of Liver Diseases Foundation Announces Funding of over $2.8 Million in Research and Career Development Awards, Abstract Awards, and Emerging Liver Scholars Program
American Association for the Study of Liver Diseases (AASLD)

The American Association for the Study of Liver Diseases (AASLD) Foundation, the largest private supporter of liver disease research and training in the United States, today announced its combined investment of over $2.8 million in Research and Career Development Awards, Abstract Awards, and its Emerging Liver Scholars (ELS) Program.

Released: 11-Dec-2020 2:30 PM EST
AASLD’s Newest Open-Access Journal to Receive First Impact Factor
American Association for the Study of Liver Diseases (AASLD)

Today the American Association for the Study of Liver Diseases (AASLD) announced that Hepatology Communications – AASLD’s free, open-access journal – has been accepted into Clarivate’s Science Citation Index Expanded (SCIE) and Journal Citation Reports – one of the leading citation indexes for journals of science and technology. The journal will now be eligible for an Impact Factor (IF) evaluation, which measures the frequency that a journal is cited and contributes to its reputation in the scientific community. Hepatology Communications will receive its first Impact Factor evaluation in the summer of 2021.

   
Released: 14-Nov-2020 4:00 PM EST
Next Editor in Chief Named for Premier Hepatology Journal
American Association for the Study of Liver Diseases (AASLD)

the American Association for the Study of Liver Diseases (AASLD) announced the appointment of the next editor in chief for their flagship journal, HEPATOLOGY. Dr. Gregory Gores, FAASLD, will take over from Dr. David Cohen, FAASLD, in January 2022, and his editorial team will begin reviewing manuscripts in July 2021.

10-Nov-2020 12:05 PM EST
UDCA Treatment Lowers Biliary Tract Cancer, Need for Liver Transplantation in PSC Patients
American Association for the Study of Liver Diseases (AASLD)

Data from a new study presented this week at The Liver Meeting Digital Experience® – held by the American Association for the Study of Liver Diseases – found that ursodeoxycholic acid (UDCA) treatment has significant, positive results for patients with primary sclerosing cholangitis (PSC), including reduced incidence of biliary tract cancer, reduced mortality and less need for liver transplant.

10-Nov-2020 12:05 PM EST
Affordable Care Act’s Medicaid Expansion Improves Liver Transplant Waitlist Placement, Especially for Certain Minorities
American Association for the Study of Liver Diseases (AASLD)

Data from a new study presented this week at The Liver Meeting Digital Experience® – held by the American Association for the Study of Liver Diseases – found that U.S. states that took part in the Affordable Care Act’s Medicaid expansion, which extended health care coverage to more low-income citizens, improved liver transplant waitlist placement, especially for certain racial groups.

10-Nov-2020 12:05 PM EST
Improved Center-Specific Practices May Ease Effects of Socioeconomic Deprivation for Pediatric Liver Transplant Recipients
American Association for the Study of Liver Diseases (AASLD)

Data from a new study presented this week at The Liver Meeting Digital Experience® – held by the American Association for the Study of Liver Diseases – found that while neighborhood socioeconomic deprivation is associated with worse adverse long-term outcomes after liver transplant in children, improving center-specific practices can mitigate these effects for young at-risk patients.

10-Nov-2020 12:05 PM EST
Alarming New Study Highlights Need for Improved Access to HBV Vaccination, Testing and Treatment
American Association for the Study of Liver Diseases (AASLD)

Data from a new study presented this week at The Liver Meeting Digital Experience® – held by the American Association for the Study of Liver Diseases – found that in 2019, more than 500,000 persons died of hepatitis B virus infection, highlighting the urgent need for universal HBV vaccination of children beginning at birth, and scaling up testing and access to care and treatment before people with the virus develop life-threatening liver cirrhosis or liver cancer.

10-Nov-2020 12:05 PM EST
New Machine Learning-Based Model More Accurately Predicts Liver Transplant Waitlist Mortality
American Association for the Study of Liver Diseases (AASLD)

Data from a new study presented this week at The Liver Meeting Digital Experience® – held by the American Association for the Study of Liver Diseases – found that using neural networks, a type of machine learning algorithm, is a more accurate model for predicting waitlist mortality in liver transplantation, outperforming the older model for end-stage liver disease (MELD) scoring. This advancement could lead to the development of more equitable organ allocation systems and even reduce liver transplant waitlist death rates for patients.

10-Nov-2020 12:05 PM EST
Unique Coagulation Driven by IL-6 Trans-Signaling Associated with Liver Injury in COVID-19
American Association for the Study of Liver Diseases (AASLD)

ALEXANDRIA, VA – Data from a new study presented this week at The Liver Meeting Digital Experience® – held by the American Association for the Study of Liver Diseases – found that COVID-19 coagulation impairment, driven in part by endothelial Factor VIII, is associated with liver injury in infected patients. The study’s findings also show that IL-6 trans-signaling, which may play a role in COVID-19 development, results in prothrombotic liver sinusoidal endothelial cells (LSECs) that may mediate the liver injury via elevated Factor VIII and activation of coagulation in the liver microvasculature.

10-Nov-2020 12:05 PM EST
New Cases of Hepatocellular Carcinoma Disproportionately Affecting Americans in Rural Areas New Study Shows
American Association for the Study of Liver Diseases (AASLD)

Data from a new study presented this week at The Liver Meeting Digital Experience® – held by the American Association for the Study of Liver Diseases – found that the rate of new hepatocellular carcinoma (HCC) cases has slowed since 2009, but only in urban areas. Rural non-Hispanic whites and Blacks have experienced the greatest increases over time when comparing rural and urban HCC trends by specific demographic factors.

10-Nov-2020 12:05 PM EST
Cirrhosis in North American Women on the Rise, Trend Especially Worrisome in Young Women
American Association for the Study of Liver Diseases (AASLD)

Data from a new study presented this week at The Liver Meeting Digital Experience® – held by the American Association for the Study of Liver Diseases – found that the burden of cirrhosis in women in North America has increased substantially in recent years, a worrying trend driven by a rise in alcohol-related liver disease (ALD) and nonalcoholic fatty liver disease (NAFLD). Projections suggest that both ALD and NAFLD rates will result in even higher cirrhosis incidence by 2040, with the most worrisome upward trends seen in young women with ALD and post-menopausal women with NAFLD.

10-Nov-2020 12:05 PM EST
High Abdominal Fat and Low Liver Fat Combo Increases Coronary Heart Disease Risk
American Association for the Study of Liver Diseases (AASLD)

Data from a new study presented this week at The Liver Meeting Digital Experience® – held by the American Association for the Study of Liver Diseases – found that the distribution of a person’s body fat affects coronary heart disease risk, with an increased risk of heart events among people with a combination of high visceral adipose tissue (VAT) – abdominal fat─ and low liver fat. The study’s findings indicate that liver triglyceride regulation plays an important role in heart health in people with discordant visceral adipose tissue and liver fat levels.

10-Nov-2020 12:05 PM EST
More Women Diagnosed with HCV During Pregnancy, but Many Infants Still Not Tested Despite Recommendations from Leading Health Organizations
American Association for the Study of Liver Diseases (AASLD)

Data from a new study presented this week at The Liver Meeting Digital Experience® – held by the American Association for the Study of Liver Diseases (AASLD)– found that among pregnant women with hepatitis C virus (HCV), more than 25 percent were initially diagnosed during pregnancy screenings, which supports prenatal care as an important opportunity to screen for HCV in women. However, the study also found that less than one third of infants receive appropriate HCV testing, a significant care gap.

27-Jul-2020 4:00 PM EDT
American Association for the Study of Liver Diseases Foundation Announces Funding of over $2.2 Million in Research and Career Development Awards, Abstract Awards, and Emerging Liver Scholars Program
American Association for the Study of Liver Diseases (AASLD)

The American Association for the Study of Liver Diseases (AASLD) Foundation, the largest private supporter of liver disease research and training in the United States, today announced its combined investment of over $2.2 million in Research and Career Development Awards, Abstract Awards, and its Emerging Liver Scholars (ELS) Program.

Released: 25-Mar-2020 1:15 PM EDT
AASLD Releases Clinical Insight Guide for Treating Patients with Liver Disease and COVID-19
American Association for the Study of Liver Diseases (AASLD)

The American Association for the Study of Liver Disease (AASLD) has released a clinical insight document for clinicians and frontline healthcare providers who are treating patients with liver disease during the COVID-19 pandemic. The document, which cites recent studies conducted in China, assesses how hepatologists and liver transplant physicians/surgeons and their patients may be affected by the COVID-19 virus (also known as SARS-CoV-2) and provides continued guidance on clinical approaches to disease management.

Released: 3-Dec-2019 3:40 PM EST
HCV Guidance Updates Recommendations for Identification and Management of Chronic Hep C
American Association for the Study of Liver Diseases (AASLD)

HCVguidelines.org — a website developed by the American Association for the Study of Liver Diseases and the Infectious Diseases Society of America to provide up-to-date guidance on the management of hepatitis C — was recently revised to reflect important developments in the identification and management of chronic hepatitis C (HCV)

Released: 20-Nov-2019 3:30 PM EST
Matthew R. D’Uva to Join AASLD as CEO
American Association for the Study of Liver Diseases (AASLD)

The American Association for the Study of Liver Diseases (AASLD) has appointed Matthew R. D’Uva, FASAE, CAE, as its new chief executive officer, effective January 21, 2020.

4-Nov-2019 8:00 AM EST
U.S. Cirrhosis Patients Often Skip or Delay Liver Cancer Surveillance Due to Cost and Lack of Insurance
American Association for the Study of Liver Diseases (AASLD)

Data from a new study presented this week at The Liver Meeting® – held by the American Association for the Study of Liver Diseases – found that cirrhosis patients in the U.S. have substantial financial burden

4-Nov-2019 8:00 AM EST
Sexual Transmission of Hepatitis C Low Among HIV-Negative Men Who Have Sex with Men on PrEP
American Association for the Study of Liver Diseases (AASLD)

Data from a new study presented this week at The Liver Meeting® – held by the American Association for the Study of Liver Diseases – found fewer new cases of hepatitis C infection (commonly called HCV), despite very high rates of other sexually-transmitted infections, in HIV-negative men who have sex with men who take pre-exposure prophylaxis (PrEP) treatments.

4-Nov-2019 8:00 AM EST
Kratom, Botanical Supplement with Opioid-Like Activity, May Cause Liver Toxicity and Injury
American Association for the Study of Liver Diseases (AASLD)

Data from a new study presented this week at The Liver Meeting® – held by the American Association for the Study of Liver Diseases – found that kratom, a popular and widely available product, may cause liver toxicity and severe liver injury.

4-Nov-2019 8:00 AM EST
Global Hepatology Societies Call for Better HCV Testing and Access to Treatment
American Association for the Study of Liver Diseases (AASLD)

Four societies focused on liver disease research and treatment announced a global call-to-action initiative to simplify hepatitis C testing and treatment.

4-Nov-2019 8:00 AM EST
A Healthy Lifestyle May Help Prevent Liver-Related Deaths
American Association for the Study of Liver Diseases (AASLD)

Data from a new study presented this week at The Liver Meeting® – held by the American Association for the Study of Liver Diseases – found that a substantial burden of hepatocellular carcinoma (HCC) and cirrhosis-related deaths may be prevented by lifestyle modifications to diet, alcohol use and exercise.

4-Nov-2019 8:00 AM EST
All-Oral Direct-Acting Antiviral Treatments Improve Survival in Patients with HCV-Related Hepatocellular Carcinoma
American Association for the Study of Liver Diseases (AASLD)

Data from a new study presented this week at The Liver Meeting® – held by the American Association for the Study of Liver Diseases – found that hepatitis C virus-related hepatocellular carcinoma (HCC) patients who achieved sustained virologic response (SVR) – denoting an undetectable level of HCV virus - with any oral direct-acting antiviral (DAA) had over 60-70 percent improvement in five-year survival.

4-Nov-2019 8:00 AM EST
NAFLD Patients Less Likely to Lose Weight, Need More Effective Weight Loss Strategies
American Association for the Study of Liver Diseases (AASLD)

Data from a new study presented this week at The Liver Meeting® – held by the American Association for the Study of Liver Diseases – found that obese individuals with nonalcoholic fatty liver disease (NAFLD) were less likely to achieve a medically recommended five percent loss of body weight at three months

4-Nov-2019 8:00 AM EST
Innovative Machine Learning Tool Predicts Who Might Have Non-Alcoholic Steatohepatitis
American Association for the Study of Liver Diseases (AASLD)

Data from a new study presented this week at The Liver Meeting® – held by the American Association for the Study of Liver Diseases – found that a machine-learning tool could successfully predict the risk of having non-alcoholic steatohepatitis (NASH) among patients with co-existing diseases.

4-Nov-2019 8:00 AM EST
Pregnant Women With Cirrhosis Have Low Levels of Liver Decompensation Within a Year of Delivery
American Association for the Study of Liver Diseases (AASLD)

Data from a new study presented this week at The Liver Meeting® – held by the American Association for the Study of Liver Diseases and funded by the AASLD Foundation

4-Nov-2019 8:00 AM EST
Could Combining Direct-Acting Antivirals with a Common Cholesterol Medication Open the Door to More Viable Organs for Transplantation?
American Association for the Study of Liver Diseases (AASLD)

Data from a new study presented this week at The Liver Meeting® – held by the American Association for the Study of Liver Diseases – found that combination therapy with direct-acting antivirals (DAAs) and ezetimibe

Released: 24-Jun-2019 4:30 PM EDT
AASLD Foundation Invests $3.42 Million in Liver Disease Research and Career Development
American Association for the Study of Liver Diseases (AASLD)

The American Association for the Study of Liver Diseases Foundation, the largest private supporter of liver disease research and training in the United States, today announced its investment of $3.42 million in Research and Career Development Awards granted to 29 researchers and clinicians to conduct innovative liver disease research and seek advanced hepatology training.

2-Nov-2018 2:30 PM EDT
Preemptive Antiviral Therapy Prevents Chronic Hepatitis C Infection in Heart Transplant Patients Who Receive Infected Donor Organs
American Association for the Study of Liver Diseases (AASLD)

SAN FRANCISCO – Preliminary data from a new study presented this week at The Liver Meeting® – held by the American Association for the Study of Liver Diseases – found that pre-emptive administration of pan-genotypic, direct-acting antiviral therapy prevents chronic hepatitis C virus infection in hepatitis C-negative cardiac transplant patients who receive donor hearts infected with the virus.

2-Nov-2018 2:30 PM EDT
Under-Immunization Still a Major Problem in Pediatric Liver Transplant Patient Population
American Association for the Study of Liver Diseases (AASLD)

SAN FRANCISCO – Data from a new study presented this week at The Liver Meeting® – held by the American Association for the Study of Liver Diseases – found that more than half of pediatric liver transplant recipients are under-immunized at the time of their transplant and are at increased risk for vaccine-preventable infections.

2-Nov-2018 2:30 PM EDT
Five Years of Regular Aspirin Use Helps Prevent Common Liver Cancer
American Association for the Study of Liver Diseases (AASLD)

SAN FRANCISCO – Data from a new study presented this week at The Liver Meeting® – held by the American Association for the Study of Liver Diseases – found that taking a regular aspirin is associated with a dose-dependent reduction in the risk of hepatocellular carcinoma, one of the most common liver cancers. The cancer risk reduction is apparent after at least five years of aspirin use, the study showed.

2-Nov-2018 2:30 PM EDT
Normothermic Machine Perfusion Can Salvage Fatty Livers for Transplantation
American Association for the Study of Liver Diseases (AASLD)

SAN FRANCISCO – Data from a new study presented this week at The Liver Meeting® – held by the American Association for the Study of Liver Diseases – found that using normothermic machine perfusion to preserve steatotic livers leads to altered lipid structure and metabolism and may result in more successful transplantation of these organs.

2-Nov-2018 2:30 PM EDT
Nonalcoholic Fatty Liver Disease Patients Have Higher Rates of All Non-Liver-Related Cancers
American Association for the Study of Liver Diseases (AASLD)

SAN FRANCISCO – Preliminary data from a new study presented this week at The Liver Meeting® – held by the American Association for the Study of Liver Diseases – found that rates of malignancy occurring outside of the liver were higher in adults with nonalcoholic fatty liver disease than among adults across most types of cancers.

2-Nov-2018 2:30 PM EDT
Universal Hepatitis C Screening of Pregnant Women More Cost-Effective Than Risk-Based Approach
American Association for the Study of Liver Diseases (AASLD)

SAN FRANCISCO – Preliminary data from a new study presented this week at The Liver Meeting® – held by The American Association for the Study of Liver Diseases – found that universal screening of pregnant women at risk for hepatitis C virus (commonly called HCV) infection is a more efficient and cost-effective diagnostic approach than risk-based screening.

2-Nov-2018 2:30 PM EDT
Combined Glecaprevir and Pibrentasvir Found Highly Effective in Chronic Hepatitis C Patients Who Have Failed Other Therapies
American Association for the Study of Liver Diseases (AASLD)

SAN FRANCISCO – Data from a new study presented this week at The Liver Meeting® – held by the American Association for the Study of Liver Diseases – found the combination of glecaprevir and pibrentasvir is highly effective and well tolerated in patients with chronic hepatitis C virus (commonly called HCV) genotype-1 infections who have prior treatment experience with sofosbuvir/NS5A inhibitor.

2-Nov-2018 2:30 PM EDT
African-Americans Face Significant Delays in Liver Transplantation Despite High Priority Scores
American Association for the Study of Liver Diseases (AASLD)

SAN FRANCISCO – Preliminary data from a new study presented this week at The Liver Meeting® – held by the American Association for the Study of Liver Diseases – found that African-American patients on waitlists for liver transplantation, despite severe disease and high scores for prioritization, persistently face significant disparities and delays in referral.

2-Nov-2018 2:30 PM EDT
People with Hepatitis C Who Actively Inject Illegal Drugs Have High Rates of Hepatitis C Treatment Adherence and Cure
American Association for the Study of Liver Diseases (AASLD)

SAN FRANCISCO – Preliminary data from a new study presented this week at The Liver Meeting® – held by the American Association for the Study of Liver Diseases – found that people who inject drugs who are infected with the hepatitis C virus have high rates of hepatitis C treatment adherence (completion of their treatment), and sustained virologic response. Based on these findings, researchers conclude these patients should be included in HCV treatment programs.

2-Nov-2018 2:30 PM EDT
Clinically Significant Liver Toxicity Related to Anti-Cancer Drugs is Rare but Often Leads to Discontinuation of Treatment
American Association for the Study of Liver Diseases (AASLD)

SAN FRANCISCO – Preliminary data from a new study presented this week at The Liver Meeting® – held by the American Association for the Study of Liver Diseases – found that patients treated with immune checkpoint inhibitors rarely develop severe liver toxicity, but the majority of those who do permanently stop this cancer treatment. None of the patients developed liver failure as a result of this treatment.


Showing results 1 – 50 of 81


close
0.21478